Principal Securities, Inc. Biotechnology

Principal Securities, Inc.

$6.07 Trillion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ATXS Astria Therapeutics, Inc.	$191M	$2.18 Million 0.0% of portfolio	300	Q3 2025 New
PTGX Protagonist Therapeutics, Inc	$4.15B	$2.13 Million 0.0% of portfolio	32	Q3 2025 Reduced 11.11%
EDIT Editas Medicine, Inc.	$179M	$2 Million 0.0% of portfolio	575	Q3 2025 Reduced 15.19%
ARWR Arrowhead Pharmaceuticals, Inc.	$4.37B	$1.79 Million 0.0% of portfolio	52	Q3 2025 Reduced 3.7%
KROS Keros Therapeutics, Inc.	$445M	$1.36 Million 0.0% of portfolio	86	Q3 2025 Added 45.76%
INMB Inmune Bio, Inc.	$26M	$1.28 Million 0.0% of portfolio	619	Q3 2025 New
MRUS Merus N.V.	$4.4B	$1.22 Million 0.0% of portfolio	13	Q2 2025 Added 85.71%
ATAI Atai Life Sciences N.V.	$664M	$1.21 Million 0.0% of portfolio	229	Q2 2025 New
QURE Uni Qure N.V.	$1.4B	$1.11 Million 0.0% of portfolio	19	Q3 2025 New

ARDX Ardelyx, Inc.	$908M	$1.1 Million 0.0% of portfolio	200	Q2 2025 New
ABUS Arbutus Biopharma Corp	$678M	$1.04 Million 0.0% of portfolio	230	Q4 2024 New
VKTX Viking Therapeutics, Inc.	$3.05B	$1.03 Million 0.0% of portfolio	39	Q2 2025 Reduced 88.6%
CVAC Cure Vac N.V.	$990M	$932,000 0.0% of portfolio	173	Q3 2025 Reduced 40.55%
REPL Replimune Group, Inc.	$443M	$905,000 0.0% of portfolio	216	Q3 2025 Added 730.77%
BBIO Bridge Bio Pharma, Inc.	$9.84B	$831,000 0.0% of portfolio	16	Q3 2025 Reduced 57.89%
NTLA Intellia Therapeutics, Inc.	$661M	$760,000 0.0% of portfolio	44	Q3 2025 Reduced 76.96%
CPRX Catalyst Pharmaceuticals, Inc.	$2.38B	$749,000 0.0% of portfolio	38	Q3 2025 Reduced 97.98%
VRNA Verona Pharma PLC	$6.52B	$747,000 0.0% of portfolio	7	Q3 2025 Reduced 69.57%

CYTK Cytokinetics Inc	$6.25B	$714,000 0.0% of portfolio	13	Q3 2025 New
ARCT Arcturus Therapeutics Holdings Inc.	$193M	$663,000 0.0% of portfolio	36	Q3 2025 Reduced 34.55%
CRBU Caribou Biosciences, Inc.	$124M	$629,000 0.0% of portfolio	270	Q3 2025 Reduced 40.92%
ADMA Adma Biologics, Inc.	$3.06B	$601,000 0.0% of portfolio	41	Q2 2025 Added 86.36%
RGNX Regenxbio Inc.	$498M	$569,000 0.0% of portfolio	59	Q2 2025 Reduced 68.78%
CLLS Cellectis S.A.	$179M	$510,000 0.0% of portfolio	179	Q2 2025 Added 244.23%
EWTX Edgewise Therapeutics, Inc.	$1.44B	$438,000 0.0% of portfolio	27	Q3 2024 New
WVE Wave Life Sciences Ltd.	$600M	$425,000 0.0% of portfolio	58	Q4 2024 Added 28.89%
CNTA Centessa Pharmaceuticals PLC	$2.6B	$412,000 0.0% of portfolio	17	Q2 2025 New
MLTX Moon Lake Immunotherapeutics	$472M	$387,000 0.0% of portfolio	54	Q3 2025 Added 575.0%
SRRK Scholar Rock Holding Corp	$1.95B	$335,000 0.0% of portfolio	9	Q2 2025 Added 125.0%
KYMR Kymera Therapeutics, Inc.	$3.55B	$283,000 0.0% of portfolio	5	Q2 2025 New
TGTX Tg Therapeutics, Inc.	$4.5B	$217,000 0.0% of portfolio	6	Q3 2025 New
VRDN Viridian Therapeutics, Inc.\De	$1.15B	$194,000 0.0% of portfolio	9	Q4 2024 New
SBTX Silverback Therapeutics, Inc.	$0	$171,000 0.0% of portfolio	17	Q2 2025 New
MREO Mereo Biopharma Group PLC	$227M	$155,000 0.0% of portfolio	75	Q2 2025 Added 134.38%
BCYC Bicycle Therapeutics PLC	$192M	$139,000 0.0% of portfolio	18	Q2 2025 New
MRVI Maravai Lifesciences Holdings, Inc.	$479M	$138,000 0.0% of portfolio	48	Q3 2025 New
RCKT Rocket Pharmaceuticals, Inc.	$231M	$137,000 0.0% of portfolio	42	Q3 2025 New
ARVN Arvinas, Inc.	$562M	$136,000 0.0% of portfolio	16	Q3 2025 Reduced 72.41%
IMMP Immutep LTD	$161M	$102,000 0.0% of portfolio	58	Q2 2025 New
GNFT Genfit S.A.	$212M	$91,000 0.0% of portfolio	24	Q2 2025 New
SLN Silence Therapeutics PLC	$247M	$88,000 0.0% of portfolio	17	Q2 2025 New
IPHA Innate Pharma Sa	$145M	$87,000 0.0% of portfolio	45	Q2 2025 New
SAVA Cassava Sciences Inc	$111M	$73,000 0.0% of portfolio	25	Q4 2024 Reduced 50.0%
AUTL Autolus Therapeutics PLC	$126M	$60,000 0.0% of portfolio	37	Q2 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Principal Securities, Inc. with notifications on news.